A survey of clinical efficacy observation:combined with Qiangxin mixture for vulnerable phase of patients
- Conditions
- Heart Failure
- Registration Number
- ITMCTR2000003980
- Lead Sponsor
- Shanghai Hospital of Traditional Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
(1) Voluntarily sign the informed consent and perform their duties;
(2) Discharged patients who meet the diagnostic criteria and participate in the test voluntarily during their stay in hospital;
(3) The condition is relatively stable and can be discharged from hospital and followed up;
(4) in patients with cardiac function II ~ III level;
(5) The age of the patient is >= 45 and <= 85 years of age, regardless of gender;
Only those who meet the above criteria can be included in the observed cases. None of them is necessary.
(1) Patients with failure of lung, liver, kidney and other important organs, namely heart failure caused by non-cardiac origin;
(2) Patients with congenital heart disease, constrictive pericarditis, severe pulmonary hypertension, obvious valvular disease, patients requiring cardiac resynchronization therapy;
(3) Patients with severe primary medical diseases such as liver, kidney and hematopoietic system;
(4) persons with mental or legal disabilities;
(5) Have participated in or will participate in other drug clinical studies;
(6) Living a bad life, such as being a chronic alcoholic or a drug addict;
(7) pregnant and lactating women;
(8) As judged by the researcher, it is not suitable to participate in this experiment;
Those who meet 1 of the above conditions cannot be taken as subjects.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method MLFHQ;The six-minute walk is the test distance (6MWT);Left ventricular ejection fraction (LVEF);Blood pressure;Heart rate;N terminal pro B type natriuretic peptide (NT-pro-BNP);Left ventricular end-diastolic diameter (LVEDD);Ventricular remodeling parameter;
- Secondary Outcome Measures
Name Time Method